XpresSpa Group Supports Airlines to Meet Dutch Travel Restrictions; XpresCheck to Pilot Rapid COVID-19 Antigen Tests for Transatlantic Flights
XpresCheck testing facilities support new rapid testing requirements for select flights with United, Delta and KLM from JFK, Newark and Boston airports into The Netherlands
NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”) announces working with major airlines carriers out of John F. Kennedy International’s Terminal 4, Newark Liberty International Airport and Boston’s Logan International Airport to the Netherlands. The Netherlands’ new COVID-19 testing policy for incoming international passengers requires a negative COVID-19 PCR test within 72 hours before departure as well as a negative COVID-19 rapid test four hours before departure. This has become the strictest travel requirement globally.
XpresCheck is collaborating with United Airlines, Delta Air Lines and KLM Royal Dutch Airlines to meet the new rapid 4-hour test requirements at select airports. In addition to its rapid molecular ABBOTT ID NOW COVID-19 tests, XpresCheck is going to pilot, at JFK Terminal 4, the implementation of a rapid antigen test next week, administering BD’s rapid SARS-CoV-2 test for the BD Veritor™ Plus System.
“XpresCheck is committed to taking a leadership position in airport COVID-19 testing to keep travelers on-track and safe,” said Doug Satzman, CEO of XpresSpa. “Whether working with these major airlines, supporting safe transatlantic flights or expanding testing capabilities, XpresCheck continuously works to meet the changing domestic and global health and travel restrictions to ensure the safest method of flying for all passengers.”
Satzman further states, “We are also going to pilot a new rapid testing extension program, operated by the gate in JFK Terminal 4, to help connecting passengers traveling to Amsterdam to meet this new restriction.”
For more information about XpresSpa please visit .
About XpresSpa Group, Inc.
XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading global health and wellness holding company. XpresSpa Group’s core asset, XpresSpa, is a leading airport retailer of spa services and related health and wellness products, with 45 locations in 23 airports globally. Through its XpresTest, Inc. subsidiary, the Company provides COVID-19 screening and testing under the XpresCheck™ brand at seven locations in six airports: Denver International Airport, JFK International Airport, Logan International Airport (2), Newark Liberty International Airport, Phoenix Sky Harbor International Airport, and Salt Lake City International Airport. To learn more about XpresSpa Group, visit:
Twitter: and Instagram:
Forward-Looking Statements
Forward-Looking Statements This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. In particular, these statements include, without limitation, statements about our expectations relating to our new XpresCheck™ concept, being able to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu, our positioning to be part of the national rollout of various COVID-19 vaccinations as they become available, the degree to which our public testing model assists passengers meet testing requirements in select states and countries, our ability to identify and gain access to the latest and best COVID-19 testing methodologies and equipment, and our ability further expand our initial sites and our overall ability to manage the regulatory challenges associated with this business line. Forward-looking statements relating to expectations about future results or events are based upon information available to XpresSpa Group as of today's date and are not guarantees of the future performance of the company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in XpresSpa Group’s most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports on Form 8-K and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XpresSpa Group, or other matters and attributable to XpresSpa Group or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XpresSpa Group does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.
Media - XpresSpa
Julie Ferguson
(312) 385-0098
Investor Relations - XpresSpa
ICR
Raphael Gross
(203) 682-8253
